Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 33

1.
3.
4.

Mouse models of chronic lung infection with Pseudomonas aeruginosa: models for the study of cystic fibrosis.

Stotland PK, Radzioch D, Stevenson MM.

Pediatr Pulmonol. 2000 Nov;30(5):413-24. Review.

PMID:
11064433
5.

Infections with Pseudomonas aeruginosa in patients with cystic fibrosis.

Tümmler B, Bosshammer J, Breitenstein S, Brockhausen I, Gudowius P, Herrmann C, Herrmann S, Heuer T, Kubesch P, Mekus F, Römling U, Schmidt KD, Spangenberg C, Walter S.

Behring Inst Mitt. 1997 Feb;(98):249-55. Review.

PMID:
9382747
6.

Topical cystic fibrosis transmembrane conductance regulator gene replacement for cystic fibrosis-related lung disease.

Lee TW, Southern KW, Perry LA, Penny-Dimri JC, Aslam AA.

Cochrane Database Syst Rev. 2016 Jun 17;(6):CD005599. doi: 10.1002/14651858.CD005599.pub5. Review.

PMID:
27314455
7.

Genotype and phenotype in cystic fibrosis.

Zielenski J.

Respiration. 2000;67(2):117-33. Review.

PMID:
10773783
9.

The role of the CFTR in susceptibility to Pseudomonas aeruginosa infections in cystic fibrosis.

Goldberg JB, Pier GB.

Trends Microbiol. 2000 Nov;8(11):514-20. Review.

PMID:
11121762
10.

Harnessing Neutrophil Survival Mechanisms during Chronic Infection by Pseudomonas aeruginosa: Novel Therapeutic Targets to Dampen Inflammation in Cystic Fibrosis.

Marteyn BS, Burgel PR, Meijer L, Witko-Sarsat V.

Front Cell Infect Microbiol. 2017 Jun 30;7:243. doi: 10.3389/fcimb.2017.00243. eCollection 2017. Review.

11.

The challenges and promises of new therapies for cystic fibrosis.

Pier GB.

J Exp Med. 2012 Jul 2;209(7):1235-9. doi: 10.1084/jem.20121248. Review.

12.

Effects of Pseudomonas aeruginosa on CFTR chloride secretion and the host immune response.

Stanton BA.

Am J Physiol Cell Physiol. 2017 Apr 1;312(4):C357-C366. doi: 10.1152/ajpcell.00373.2016. Epub 2017 Jan 25. Review.

13.

Lung infections associated with cystic fibrosis.

Lyczak JB, Cannon CL, Pier GB.

Clin Microbiol Rev. 2002 Apr;15(2):194-222. Review.

14.

Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice.

Castellani C, Cuppens H, Macek M Jr, Cassiman JJ, Kerem E, Durie P, Tullis E, Assael BM, Bombieri C, Brown A, Casals T, Claustres M, Cutting GR, Dequeker E, Dodge J, Doull I, Farrell P, Ferec C, Girodon E, Johannesson M, Kerem B, Knowles M, Munck A, Pignatti PF, Radojkovic D, Rizzotti P, Schwarz M, Stuhrmann M, Tzetis M, Zielenski J, Elborn JS.

J Cyst Fibros. 2008 May;7(3):179-96. doi: 10.1016/j.jcf.2008.03.009. Review.

15.

Strategies for identifying modifier genes in cystic fibrosis.

Boyle MP.

Proc Am Thorac Soc. 2007 Jan;4(1):52-7. Review.

16.

Cystic fibrosis lung environment and Pseudomonas aeruginosa infection.

Bhagirath AY, Li Y, Somayajula D, Dadashi M, Badr S, Duan K.

BMC Pulm Med. 2016 Dec 5;16(1):174. Review.

17.

Hepatobiliary complications of cystic fibrosis.

Feranchak AP.

Curr Gastroenterol Rep. 2004 Jun;6(3):231-9. Review.

PMID:
15128491
18.

Impact of mannose-binding lectin insufficiency on the course of cystic fibrosis: A review and meta-analysis.

Chalmers JD, Fleming GB, Hill AT, Kilpatrick DC.

Glycobiology. 2011 Mar;21(3):271-82. doi: 10.1093/glycob/cwq161. Epub 2010 Nov 2. Review.

PMID:
21045008
19.

Recent advances in cystic fibrosis.

Doull IJ.

Arch Dis Child. 2001 Jul;85(1):62-6. Review.

20.

Update on gene modifiers in cystic fibrosis.

Collaco JM, Cutting GR.

Curr Opin Pulm Med. 2008 Nov;14(6):559-66. doi: 10.1097/MCP.0b013e3283121cdc. Review.

Supplemental Content

Support Center